|
Anti-angiogenic therapies for metastatic colorectal cancer. |
60.00% |
|
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo |
60.00% |
|
Case report of a pituitary macroadenoma treated with artemether. |
50.00% |
|
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. |
80.00% |
|
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient |
80.00% |
|
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. |
40.00% |
|
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. |
80.00% |
|
How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. |
80.00% |
|
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and |
50.00% |
|
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. |
40.00% |
|
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. |
80.00% |
|
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. |
70.00% |
|
N-acetylcysteine inhibits proliferation, adhesion, migration and invasion of human bladder cancer cells. |
80.00% |
|
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe |
50.00% |
|
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of |
60.00% |
|
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre |
70.00% |
|
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma |
70.00% |
|
Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour ce |
80.00% |
|
Chemical analyses of Ukrain, a semi-synthetic Chelidonium majus alkaloid derivative, fail to confirm its trimeric structure |
90.00% |
|
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. |
40.00% |
|
Medicinal plants and cancer chemoprevention. |
90.00% |
|
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort |
80.00% |
|
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe |
30.00% |
|
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. |
40.00% |
|
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. |
50.00% |
|
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. |
70.00% |
|
Artesunate in the treatment of metastatic uveal melanoma--first experiences. |
90.00% |
|
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. |
60.00% |
|
Brain tumour cells killed by anti-nausea drug |
70.00% |
|
Clinical management of adrenocortical carcinoma |
60.00% |
|
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu |
70.00% |
|
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. |
70.00% |
|
Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series |
|
|
Effects of CANELIM capsule drug-contained serum on viscoelasticity |
90.00% |
|
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ |
|
|
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m |
60.00% |
|
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate |
60.00% |
|
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds |
80.00% |
|
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. |
60.00% |
|
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. |
80.00% |
|
Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. |
70.00% |
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat |
40.00% |
|
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention |
90.00% |
|
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... |
60.00% |
|
Spike Protein Goes to Nucleus and Impairs DNA Repair (In-Vitro Study) |
|
|
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel |
60.00% |
|
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. |
80.00% |
|
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer |
70.00% |
|
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary |
50.00% |
|
To widen the setting of cancer patients who could benefit from metronomic capecitabine. |
80.00% |
|
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic soli |
90.00% |
|
Ukrain (NSC-631570) in the treatment of pancreas cancer. |
95.00% |
|
Ukrain (NSC-631570) influences on bone status: a review. |
50.00% |
|
Unconventional anticancer agents: a systematic review of clinical trials. |
60.00% |
|
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. |
|
|
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and |
90.00% |
|
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. |
100.00% |
|
42 year old man. Kidney cancer |
90.00% |
|
61 year old woman, Breast cancer with lymph, and lung metastasis |
90.00% |
|
63 year old woman with stage III malignant melanoma |
100.00% |
|
66 year man. Cholangiocarcinoma |
80.00% |
|
71 year old woman, Pancraetic cancer with liver and lung metastasis. |
90.00% |
|
71 year old woman. Breast cancer with bone metastasis |
90.00% |
|
75 year old man, Prostate Cancer with bone and liver metastasis |
100.00% |
|
82 year old man with prostate cancer |
85.00% |
|
82 year old woman. Breast cancer with lymph and bone metastasis. |
80.00% |
|
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. |
90.00% |
|
A case of metronomic chemotherapy as an alternative cancer therapy for palliation |
60.00% |
|
A comparative evaluation of the influence of the complex drug Ukrain and its components on the effects of radiation |
80.00% |
|
A homeopathic approach to treat patients with advanced gallbladder, periampullary, and liver carcinomas: a report of 3 cases. |
90.00% |
|
A lipoxygenase inhibitor in breast cancer brain metastases. |
80.00% |
|
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study |
50.00% |
|
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... |
50.00% |
|
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
|
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... |
50.00% |
|
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. |
50.00% |
|
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. |
40.00% |
|
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. |
50.00% |
|
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. |
70.00% |
|
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... |
60.00% |
|
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot |
70.00% |
|
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. |
60.00% |
|
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma |
80.00% |
|
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... |
30.00% |
|
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. |
70.00% |
|
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) |
50.00% |
|
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with metastatic bladder cancer. |
100.00% |
|
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable m |
100.00% |
|
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable metastatic colorectal carcinoma. |
100.00% |
|
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced esoph |
90.00% |
|
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-s |
100.00% |
|
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. |
50.00% |
|
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. |
|
|
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi |
60.00% |
|
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal |
100.00% |
|
A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. |
80.00% |
|
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung |
50.00% |
|
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... |
90.00% |
|
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation |
50.00% |
|
A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. |
90.00% |
